Luspatercept is a novel fusion protein that blocks TGF-β superfamily ligands, such as GDF-11 and activin B, thereby restoring late-stage erythropoiesis in anemic lower-risk MDS patients [8, 9]. Here, TGFB1 is linked to myelodysplastic syndrome.